【作者】 王峰； 潘跃银； 胡世莲；

【Author】 Wang Feng;Pan Yueyin;HU Shilian;The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China;Anhui Provincial key laboratory of tumor immunotherapy and nutritional therapy;

【机构】 中国科学技术大学附属第一医院； 肿瘤免疫与营养治疗安徽省重点实验室；

【摘要】 目的探讨单药吉西他滨治疗晚期乳腺癌的临床疗效及安全性分析。方法将中国科学技术大学附属第一医院集团肿瘤科收治的81例晚期乳腺癌患者(收治时间为2017年1月～2020年3月)纳入本项分析研究中,均为既往蒽环类和紫杉类化疗后出现耐药的患者。回顾性分析治疗历程中患者采用单药吉西他滨治疗的近期疗效、不良反应发生情况。结果本研究组患者的客观缓解率和疾病控制率分别是20.0%和77.5%;患者的中位无进展生存期为5.0月,出现的不良反应有:白细胞减少(或中性粒细胞减少)(40例)、血小板减少(8例)、贫血(9例)、恶心(6例)、呕吐(0例)、口腔炎(0例)、高胆红素血症(3例)、转氨酶升高(4例)、蛋白尿(0例)、血清肌酐升高(1例)、间质性肺炎(0例)、肺水肿(0例)、发热(1例)、头痛(0例)、心律失常(1例)、皮疹(1例)和瘙痒(1例)。结论对于使用蒽环类、紫杉类等药物化疗失败的晚期乳腺癌患者,采用单药吉西他滨化疗具有显著有效性和安全性。更多还原

【Abstract】 Objective To investigate the efficacy and safety of gemcitabine as a single agent in the treatment of advanced breast cancer.Methods 81 patients with advanced breast cancer at who demonstrated resistance to anthracycline and paclitaxel-based chemotherapy were included.All enrolled patients were admitted to the oncology department of the first affiliated hospital of the USTC.The short-term efficacy and adverse reactions of gemcitabine were retrospectively analyzed.Results The ORR and DCR of the patients in the study were(20.0%)and(77.5%) respectively.The mPFS was 5.0 m.The adverse reactions included:leucopenia or neutropenia(40),thrombocytopenia(8),anemia(9),nausea(6),vomiting(0),stomatitis(0),hyperbilirubinemia(3),ALT/AST elevation(4),proteinuria(0)、elevated serum creatinine(1)、interstitial pneumonia(0),pulmonary edema(0),fever(1),headache(0),arrhythmia(0),rash(1) and pruritus(1).Conclusion Chemotherapy with gemcitabine alone is effective and safe for advanced breast cancer patients who demonstrated resistance to anthracycline and paclitaxel-based chemotherapy.更多还原